# Mirabegron in Parkinson Disease and Impaired Cognition

> **NCT02536976** · PHASE4 · COMPLETED · sponsor: **HealthPartners Institute** · enrollment: 7 (actual)

## Conditions studied

- Parkinson Disease
- Overactive Bladder
- Impaired Cognition

## Interventions

- **DRUG:** mirabegron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02536976
- **Lead sponsor:** HealthPartners Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2018-08-01
- **Final completion:** 2018-08-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536976, "Mirabegron in Parkinson Disease and Impaired Cognition". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02536976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*